title: Validation and ease of use of a new pen device for self-administration of recombinant human growth hormone: results from a two-center usability study.
abstract: Close adherence to the recommended treatment regimen is important for the success of recombinant human growth hormone therapy, although nonadherence can be common. Ease of use and safety during use/storage are among several important factors in the design of a growth hormone injection device intended for long-term use. This study was performed to validate the usability and assess the ease of use of a new pen device (SurePal™) that has been developed to support daily administration of the recombinant human growth hormone product, Omnitrope® (somatropin). The primary objectives of the study were to assess if study participants, representing intended users of the pen in clinical practice, were able to perform an injection procedure into an injection pad effectively and safely and disassemble the pen without receiving a needlestick injury. A total of 106 participants (61 adults and 45 children/adolescents) were enrolled at two study centers (one in the US, one in Germany). Results for both primary usability tasks met the predefined acceptance criteria, with >85% of participants successfully performing each task. All of the other tasks/handling steps assessed were also successfully performed by most participants, with high success rates reflected in the high proportion of participants who classified each task as "very easy" or "easy". After a second use of the device, 87%-97% of participants rated it as "very easy" or "easy" to use. In summary, the new pen device is safe and easy to use for both adults and children, and will help to support effective, long-term daily administration of the recombinant human growth hormone product, Omnitrope®.
authors.affiliation: Division of Pediatric Endocrinology and Diabetes, Mount Sinai School of Medicine, Mineola, NY, USA.
authors.forename: Robert
authors.initials: R
authors.lastname: Rapaport
authors.forename: Paul
authors.initials: P
authors.lastname: Saenger
authors.forename: Heinrich
authors.initials: H
authors.lastname: Schmidt
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Hasegawa
authors.forename: Michel
authors.initials: M
authors.lastname: Colle
authors.forename: Sandro
authors.initials: S
authors.lastname: Loche
authors.forename: Sandra
authors.initials: S
authors.lastname: Marcantonio
authors.forename: Walter
authors.initials: W
authors.lastname: Bonfig
authors.forename: Markus
authors.initials: M
authors.lastname: Zabransky
authors.forename: Fima
authors.initials: F
authors.lastname: Lifshitz
keywords: Omnitrope®; SurePal™; ease of use; growth hormone; pen device
references.citation: J Clin Endocrinol Metab. 2000 Nov;85(11):3990-3
references.pmid: 11095419
references.citation: J Clin Endocrinol Metab. 1997 Feb;82(2):452-6
references.pmid: 9024235
references.citation: Clin Ther. 2010 Oct;32(11):1918-34
references.pmid: 21095487
references.citation: Arch Dis Child. 2008 Feb;93(2):110-4
references.pmid: 17412745
references.citation: Eur J Endocrinol. 2005 Feb;152(2):165-70
references.pmid: 15745921
references.citation: J Spec Pediatr Nurs. 2011 Jan;16(1):50-63
references.pmid: 21294835
references.citation: Cochrane Database Syst Rev. 2008 Apr 16;(2):CD000011
references.pmid: 18425859
references.citation: Eur J Endocrinol. 2007 Dec;157(6):695-700
references.pmid: 18057375
references.citation: Clin Ther. 2008 Feb;30(2):307-16
references.pmid: 18343269
references.citation: Acta Paediatr. 1998 Apr;87(4):387-91
references.pmid: 9628292
references.citation: BMC Endocr Disord. 2006 Oct 11;6:5
references.pmid: 17034628
references.citation: Pediatr Ann. 2012 Apr;41(4):e1-9
references.pmid: 22494211
references.citation: Patient Prefer Adherence. 2011 Mar 10;5:117-24
references.pmid: 21448295
references.citation: Endocr Pract. 2003 Jan-Feb;9(1):64-76
references.pmid: 12917095
references.citation: PLoS One. 2011 Jan 31;6(1):e16223
references.pmid: 21305004
references.citation: Diabetes Technol Ther. 2010 Feb;12(2):143-8
references.pmid: 20105044
references.citation: J Hosp Infect. 2006 May;63(1):60-4
references.pmid: 16540200
references.citation: Endocr Pract. 2008 Mar;14(2):143-54
references.pmid: 18308651
references.citation: J Clin Endocrinol Metab. 2007 Jan;92(1):10-25
references.pmid: 17047017
references.citation: Clin Ther. 2009 Dec;31(12):2906-14
references.pmid: 20110030
references.citation: Arch Dis Child. 1993 Jan;68(1):91-3
references.pmid: 8435018
references.citation: Arch Dis Child. 2008 Feb;93(2):147-8
references.pmid: 17768149
references.citation: Pediatr Nephrol. 2006 Jul;21(7):917-30
references.pmid: 16773402
references.citation: J Clin Endocrinol Metab. 2007 Mar;92(3):804-10
references.pmid: 17200164
references.citation: Clin Ther. 2010 Nov;32(12):2036-47
references.pmid: 21118739
references.citation: Eur J Endocrinol. 2009 Jun;160(6):899-907
references.pmid: 19324976
references.citation: ISRN Endocrinol. 2011;2011:803948
references.pmid: 22363887
references.citation: Horm Res. 2006;65(1):18-22
references.pmid: 16357486